Blastic plasmacytoid dendritic cell neoplasm: A clinicopathologic review

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 4, 2014, Pages 564-569

  Shi, Yang ^a   Wang, Endi ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN;

ACUTE MYELOMONOCYTIC LEUKEMIA; CANCER STEM CELL; DENDRITIC CELL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PATHOLOGY; REVIEW; SKIN TUMOR;

ANTIGENS, CD; DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOMONOCYTIC, ACUTE; NEOPLASTIC STEM CELLS; SKIN NEOPLASMS;

EID: 84898467743     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0101-RS     Document Type: Review

References (20)

1. Herling M, Jones D. CD4/CD56hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007; 127(5):687-700.
2. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cells neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon France: IARC Press; 2008:146-147. World Health Organization Classification of Tumours; vol
3. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4CD56 malignancies. Blood. 2002;99(5):1556-1563.
4. Jacob MC, Chaperot L, Mossuz P, et al. CD4 CD56 lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88(8):941-955.
5. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4CD56 hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-675.
6. Wang H, Cao J, Hong X. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. Acta Haematol. 2012;127(2):124-127.
7. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2S) and the related CD4 CD56 blastic tumors of skin. Blood. 2003;101(12):5007-5009.
8. Assaf C, Gellrich S, Whittaker S, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol. 2007;60(9):981-989.
9. Petrella T, Comeau MR, Maynadie M, et al. 'Agranular CD4 CD56 hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56 precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26(7):852-862.
10. Petrella T, Dalac S, Maynadie M, et al. CD4 CD56 cutaneous neoplasms: a distinct hematological entity: Groupe Fraņcais d'Etude des Lymphomes Cutan'es (GFELC). Am J Surg Pathol. 1999;23(2):137-146.
11. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122(2):307-313.
12. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
13. Leroux D, Mugneret F, Callanan M, et al. CD4, CD56 DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fraņcais de Cytog'en'etique H'ematologique. Blood. 2002;99(11):4154-4159.
14. Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011;118(17):4591-4594.
15. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med. 1997;185(6):1101-1111.
16. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16(6):392-404.
17. Petrella T, Facchetti F. Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009 Autoimmunity. 2010;43(3):210-214.
18. Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2011;153(3):413-416.
19. Roos-Weil D, Dietrich S, Boumendil A, et al; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) [published online ahead of print November 30, 2012]. Blood. 2013;121(3): 440-446. doi:10.1182/blood-2012- 08-448613.
20. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.